Paul Krzyzanowski

Paul is a computational biologist and writer living in Toronto. He's been a contributor to Signals for three years, writing articles for the general public about how biotechnology and biomedical research can be used to solve pressing medical problems. Alongside Paul's experience in computational biology,
 bioinformatics, and molecular genetics, he's interested in how academic research develops into real world, commercial technology, and what's needed for the Canadian biotech industry needs to grow. Paul is currently a Post-doctoral Fellow at the Ontario Institute of Cancer Research. Prior to joining the OICR, he worked at the Ottawa Hospital Research 
Institute and earned a Ph.D. from the University of Ottawa, specializing in computational biology. And finally, Paul earned an H.B.Sc. from the University of Toronto a long time ago. Paul's blog can be read at www.checkmatescientist.net

Posts by: Paul


The out of this world story behind Endonovo’s regenerative medicine technology

Author: Paul Krzyzanowski, 05/25/16

A few weeks ago, I came across an interesting story about a stem cell company with a peculiar patenting strategy. As I looked into it further, I realized I’d stumbled into a complicated corporate plot that became more incredible with every turn. Endonovo Therapeutics is pursuing patents around molecules produced from adult stem cells which,…Read more

Micromanagement of bioethics isn’t ethical

Author: Paul Krzyzanowski, 09/10/15

. Bioethicists have had ample time this summer for self-reflection, following Steven Pinker’s op-ed in The Boston Globe that’s informally become known as the “Get out of the way” article. I’ve always found Pinker to be one of my favourite authors due to the fact his arguments are thoroughly reasoned, so I have been slightly…Read more

Sticky cells are the key to printing 3D organs

Author: Paul Krzyzanowski, 07/23/15

. It’s been about 50 years since Philip K. Dick, one of the greatest science fiction authors, introduced the idea of artificial organs replacing failing or diseased organs. In his novel, Ubik, the author writes: “[Glen] Runciter’s body contained a dozen artiforgs, artificial organs grafted into place in his physiological apparatus as the genuine, original…Read more

Cellular Dynamics takes Fujifilm from cameras to combination products

Author: Paul Krzyzanowski, 05/21/15

. By now, many of you will have heard of Fujifilm’s USD$307 million purchase of Cellullar Dynamics International (CDI). This may seem like a major entry into the regenerative medicine (RM) space for a company that’s better known for its imaging technologies than something as complex as the cell therapy space. However, the move seems to…Read more

No link between STAP cells and acid reflux, except for paper’s authors

Author: Paul Krzyzanowski, 04/22/14

> If you’ve stayed current with the STAP cell fiasco you know it’s been a wild ride. STAP cells, or Stimulus-Triggered Acquisition of Pluripotency cells, caught the imagination of many in late January through their sheer simplicity: You hit cells with a shock of acidic conditions, and they become pluripotent. That’s it. No Yamanaka factors…Read more

Human brains, frozen for 11 years, still yield pluripotent stem cells

Author: Paul Krzyzanowski, 01/09/14

> If your morning cup of coffee wasn’t enough to wake you up today, researchers from the New York Stem Cell Foundation and Columbia University just reported being able to generate iPS cells from human brain tissue that’s been frozen for 11 years: Induced pluripotent stem cells (iPSCs) derived from patients with neurodegenerative disease generally…Read more

“Freedom to operate” strategy positions BioTime for rapid growth

Author: Paul Krzyzanowski, 12/16/13

> This is part three of an interview series with Michael West, CEO of BioTime. Read parts one and two.  The prospects for BioTime and other companies that operate in the tissue engineering and cell therapy market are good. The industry is growing by about 18% per year and is estimated to reach $11 billion…Read more

The many opportunities for products in the stem cell field: An interview with Michael West, part 2

Author: Paul Krzyzanowski, 10/08/13

This is part two of a series on Michael West. Read part one. When most people hear of new applications coming out of stem cell research it’s usually via headline grabbing soon-to-be-products like stem cell derived livers, replacement ears, transplantable retinas, among other potentially useful things. Any one of these applications has the chance of…Read more

The ever changing stem cell field: An interview with Michael West

Author: Paul Krzyzanowski, 09/10/13

. Earlier this summer I had the fortunate opportunity to speak with Dr. Michael West, of BioTime, and pick his brain on various aspects of the stem cell industry, what it’s faced, and where it might go. It was a perfect follow up to my post in March that explored BioTime’s acquisition of Geron’s stem…Read more

Stem cell detective work: How George Daley uncovers iPS cells’ secrets

Author: Paul Krzyzanowski, 07/03/13

George Daley (File photo) Immediately after last month’s ISSCR meeting, George Daley travelled to the University of Toronto where he had been invited to be an external reviewer on a PhD thesis defense. While there, Daley spoke to a packed audience interested in what he had to say about cell differentiation. In Boston just days…Read more